Abstracts tagged "Janus kinase (JAK)"

Abstract Number: 557 • 2018 ACR/ARHP Annual Meeting
The Impact of Comedication with Conventional Synthetic Dmards on Drug Retention and Clinical Effectiveness of Tofacitinib, Anti–Tumor Necrosis Factor Therapy and Biologics with an Alternative Mode of Action in Patients with Rheumatoid Arthritis. a Cohort Study
Axel Finckh¹, Christophe Tellenbach², Almut Scherer², Burkhard Moeller³, Adrian Ciurea⁴, Ines von Mühlenen⁵, Cem Gabay⁶, Diego Kyburz⁷, Ruediger Mueller⁸, Paul Hasler⁹ and Pascal Zufferey¹⁰, ¹University Hospital of Geneva, Geneva, Switzerland, ²SCQM Foundation, Zurich, Switzerland, ³Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁵Rheuma-Basel, Basel, Switzerland, ⁶University Hospitals of Geneva, Geneva, Switzerland, ⁷Rheumatology, University Hospital Basel, Basel, Switzerland, ⁸Division of Rheumatology, Kantonsspital St Gallen, St. Gallen, Switzerland, ⁹Kantonsspital Aarau AG, Aarau, Switzerland, ¹⁰Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland
Background/Purpose: Co-medication with conventional synthetic DMARDs (csDMARDs) is currently recommended with all targeted therapies (bDMARDs and tsDMARDs) for the management of rheumatoid arthritis (RA). However,…
Abstract Number: 1894 • 2018 ACR/ARHP Annual Meeting
Baricitinib-Associated Changes in Type l Interferon Gene Signature during a 24-Week Phase-2 Clinical SLE Trial
Thomas Dörner¹, Yoshiya Tanaka², Michelle Petri³, Josef S. Smolen⁴, Ernst R. Dow⁵, Richard E. Higgs⁵, Robert J. Benschop⁵, Adam Abel⁵, Maria E. Silk⁵, Stephanie de Bono⁵ and Robert W. Hoffman⁵, ¹Charité Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁵Eli Lilly and Company, Indianapolis, IN
Background/Purpose: In the phase 2 study JAHH (NCT02708095), treatment with baricitinib (bari), an oral selective Janus kinase 1/2 inhibitor approved for the treatment of RA,…
Abstract Number: 599 • 2018 ACR/ARHP Annual Meeting
Comparative Effectiveness in Pain and HAQ-DI Improvement for Baricitinib Versus Adalimumab, Tocilizumab, and Tofacitinib Monotherapies in Csdmard-Naïve Rheumatoid Arthritis Patients: A Matching-Adjusted Indirect Comparison (MAIC)
Bruno Fautrel¹, Baojin Zhu², Peter C. Taylor³, Mart van de Laar⁴, Paul Emery⁵, Francesco de Leonardis², Carol L. Gaich², Claudia Nicolay², Zbigniew Kadziola², Inmaculada de la Torre⁶ and Roy Fleischmann⁷, ¹University Pierre et Marie Curie, Paris, France, ²Eli Lilly and Company, Indianapolis, IN, ³Botnar Research Centre, Univ of Oxford, Oxford, United Kingdom, ⁴Arthritis Centre Twente, University of Twente, Enschede, Netherlands, ⁵Leeds MSK Biomed/Chapel Allerton Hospital, Leeds, United Kingdom, ⁶Eli Lilly and Company, Madrid, Spain, ⁷Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: In Phase 3 trial (RA-BEGIN), baricitinib (BARI) monotherapy demonstrated superiority to MTX in pain reduction and HAQ-DI improvement in treatment of csDMARD-naïve active RA…
Abstract Number: 2035 • 2018 ACR/ARHP Annual Meeting
Effect of Baricitinib on Joint-Related Biomarkers in Patients with Moderate-to-Severe Rheumatoid Arthritis
Christian S. Thudium¹, Anne C. Bay-Jensen¹, Suntara Cahya², Ernst R. Dow², Morten A. Karsdal¹, Alisa E. Koch², Wenling Zhang² and Robert J. Benschop², ¹Nordic Bioscience, Herlev, Denmark, ²Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (bari) is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK2. In the phase 3 study RA-BUILD (NCT01721057), once-daily bari yielded…
Abstract Number: 887 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Dmards
Yoshiya Tanaka¹, Tsutomu Takeuchi², Sakae Tanaka³, Atsushi Kawakami⁴, Manabu Iwasaki⁵, Yeong Wook Song⁶, Yi-Hsing Chen⁷, Mitsuhiro Rokuda⁸, Hiroyuki Izutsu⁸, Satoshi Ushijima⁸, Yuichiro Kaneko⁸, Teruaki Shiomi⁸ and Emi Yamada⁸, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Nagasaki University, Nagasaki, Japan, ⁴University of Tokyo, Tokyo, Japan, ⁵Yokohama City University, Yokohama, Japan, ⁶Seoul National University Hospital, Seoul, Korea, Republic of (South), ⁷Taichung Veterans General Hospital, Taichung City, Taiwan, ⁸Astellas Pharma, Inc., Tokyo, Japan
Background/Purpose: Peficitinib (ASP015K), a novel oral JAK inhibitor, demonstrated efficacy as once-daily monotherapy in patients with moderate to severe RA in a phase 2b study…
Abstract Number: 2065 • 2018 ACR/ARHP Annual Meeting
Blockade of the JAK/STAT Pathway Inhibits Inflammation and Bone Formation in Two Murine Models of Spondyloarthritis
Yukiko Maeda¹, Zheni Stavre¹, Tingting Huang², Catherine Manning², Bryant Shaughn³, Michael Macoritto³, Deborah Hyland³, Wendy Waegell³ and Ellen M. Gravallese⁴, ¹Medicine, University of Massachusetts Medical School, Worcester, MA, ²Medicine, University of Massachusetts Medical School, worcester, MA, ³Abbvie Bioresearch Center, worcester, MA, ⁴Lazare Research Bldg, University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Spondyloarthritis (SpA) results in significant pain and loss of function due to inflammation and resulting enthesial/periosteal bone formation. Inhibition of the Janus kinase (JAK)/STAT…
Abstract Number: 888 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Methotrexate
Tsutomu Takeuchi¹, Yoshiya Tanaka², Sakae Tanaka³, Atsushi Kawakami⁴, Manabu Iwasaki⁵, Mitsuhiro Rokuda⁶, Hiroyuki Izutsu⁶, Satoshi Ushijima⁶, Yuichiro Kaneko⁶, Teruaki Shiomi⁶ and Emi Yamada⁶, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Nagasaki University, Nagasaki, Japan, ⁴University of Tokyo, Tokyo, Japan, ⁵Yokohama City University, Yokohama, Japan, ⁶Astellas Pharma, Inc., Tokyo, Japan
Background/Purpose: Peficitinib (ASP015K), a novel oral JAK inhibitor, demonstrated efficacy as once-daily monotherapy in patients with moderate-to-severe RA in a phase 2b study (NCT01649999)1. We…
Abstract Number: 2097 • 2018 ACR/ARHP Annual Meeting
Monotherapy with Filgotinib, a JAK1-Selective Inhibitor, Reduces Disease Severity and Alters Immune Cell Subsets in the NZB/W F1 Murine Model of Lupus
Pei Han¹, Christopher Pohlmeyer¹, Ching Shang¹, Zhihua Cui², David Lopez³, Astrid Clarke², Randall Jones², Nevena Mollova³, Igor Mikaelian⁴, David Newstrom³, Shiva Zaboli³, Allyson Shauf³ and Julie Di Paolo⁵, ¹Immunology and Inflammation, Gilead Sciences, Foster City, CA, ²Gilead Sciences, Seattle, WA, ³Gilead Sciences, Foster City, CA, ⁴Biology Core Support, Gilead Sciences, Foster City, CA, ⁵Immunology and Inflammation Biology, Gilead Sciences, Inc., Foster City, CA
Background/Purpose: SLE is a heterogeneous autoimmune disease characterized by immune system hyper-activation leading to the production of autoantibodies and immune attack on multiple organs including…
Abstract Number: 889 • 2018 ACR/ARHP Annual Meeting
Upadacitinib As Monotherapy: A Phase 3 Randomized Controlled Double-Blind Study in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Josef S. Smolen¹, Stanley Cohen², Paul Emery³, William F C Rigby⁴, Yoshiya Tanaka⁵, Ying Zhang⁶, Alan Friedman⁶, Ahmed A. Othman⁶, Heidi S. Camp⁶ and Aileen L. Pangan⁶, ¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²Metroplex Clinical Research Center, Dallas, TX, ³Leeds Inst of Rheumatic & Musculoskeletal Medicine, Leeds NIHR BRC, United Kingdom, ⁴Dartmouth College, Hanover, NH, ⁵Univ of Occupational and Environmental Health, Kitakyushu, Japan, ⁶AbbVie, North Chicago, IL
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, showed efficacy in rheumatoid arthritis (RA) patients (pts) with an inadequate response to csDMARDs or bDMARDs on continuing…
Abstract Number: 2103 • 2018 ACR/ARHP Annual Meeting
Using a Drosophila Model to Unravel the Genetic Complexity of Systemic Lupus Erythematosus
Nathan Mortimer, Mary Fischer, Ashley Waring and Victoria DeMichel, School of Biological Sciences, Illinois State University, Normal, IL
Background/Purpose: The objective of our research is to understand the genetic architecture and molecular mechanisms that contribute to the development and progression of the autoimmune…
Abstract Number: 10L • 2017 ACR/ARHP Annual Meeting
Upadacitinib (ABT-494) in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological Dmards: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of a Selective JAK-1 Inhibitor
Mark C. Genovese¹, Roy Fleischmann², Bernard Combe³, Stephen Hall⁴, Ying Zhang⁵, Yijie Zhou⁵, Mohamed-Eslam F. Mohamed⁶, Sebastian Meerwein⁷ and Aileen L. Pangan⁵, ¹Stanford University Medical Center, Palo Alto, CA, ²University of Texas Southwestern Medical Center at Dallas, Dallas, TX, ³Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ⁴Department of Medicine, Monash University, Cabrini Health and Emeritus Research, Malvern, Australia, ⁵AbbVie Inc., North Chicago, IL, ⁶Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, ⁷AbbVie Deutschland GmbH & Co, Ludwigshafen, Germany

Background/Purpose: Upadacitinib (ABT-494, UPA), an oral, selective JAK-1 inhibitor was effective in 2 ph2 trials in rheumatoid arthritis (RA) pts with inadequate response (IR)/intolerance to…
Abstract Number: 16L • 2017 ACR/ARHP Annual Meeting
Incidence of Thromboembolic Events in the Tofacitinib Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis and Ulcerative Colitis Development Programs
Philip J Mease¹, Joel Kremer², Stanley Cohen³, Jeffrey R Curtis⁴, Christina Charles-Schoeman⁵, Edward V Loftus⁶, Jeffrey D Greenberg⁷, Niki Palmetto⁸, Keith S Kanik⁹, Daniela Graham⁹, Cunshan Wang⁹, Pinaki Biswas⁸, Gary Chan¹⁰, Ryan DeMasi¹⁰, Hernan Valdez⁸, Thijs Hendrikx¹⁰ and Thomas V Jones¹⁰, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ³Metroplex Clinical Research Center, Dallas, TX, ⁴University of Alabama, Birmingham, AL, ⁵University of California, Los Angeles, CA, ⁶Mayo Clinic, Rochester, MN, ⁷Corrona, LLC, Southborough, MA, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, Collegeville, PA

Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor that preferentially inhibits signaling by JAK3 and JAK1, with functional selectivity over JAK2. Potential increased risk…
Abstract Number: 510 • 2017 ACR/ARHP Annual Meeting
Association between Clinical Response and Normalization of Patient-Reported Outcome Measures in Rheumatoid Arthritis: Post-Hoc Analysis from Two Phase 2b Filgotinib Studies
Mark C. Genovese¹, Annegret Van der Aa², Corinne Jamoul², Chantal Tasset², Pille Harrison², René Westhovens³ and Arthur Kavanaugh⁴, ¹Stanford University Medical Center, Palo Alto, CA, ²Galapagos NV, Mechelen, Belgium, ³University Hospitals Leuven on behalf of the CareRA Study Group, Leuven, Belgium, ⁴Medicine, University of California, San Diego, La Jolla, CA
Background/Purpose: Filgotinib (GLPG0634, GS-6034) is an oral, selective JAK1 inhibitor that has demonstrated safety and efficacy data in two 24-week placebo-controlled phase 2B studies as…
Abstract Number: 2568 • 2017 ACR/ARHP Annual Meeting
Prophylactic and Therapeutic Administration of a JAK1-Selective Inhibitor Blocks and Reverses Nephritis and Sialadenitis in NZB/W-F1 Mice
Rachel Twomey¹, Stuart Perper¹, Susan Westmoreland¹, Terry Melim¹, Soumya Mitra¹, Zheng Liu¹, Manuel Duval¹, Carolyn Cuff², Andrew Long¹, Anthony Slavin² and Stephen Clarke¹, ¹AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²Immunology Discovery, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: Signaling of most cytokine receptors occurs through the JAK-STAT pathway. This is true of cytokines linked to the etiology of systemic lupus erythematosus (SLE)…
Abstract Number: 511 • 2017 ACR/ARHP Annual Meeting
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 5.5 Years: An Updated Integrated Safety Analysis
Mark C. Genovese¹, Josef S. Smolen², Tsutomu Takeuchi³, David Hyslop⁴, William L. Macias⁴, Terence P. Rooney⁴, Lei Chen⁴, Christina L. Dickson⁴, Jennifer Riddle Camp⁴, Tracy Cardillo⁴, Taeko Ishii⁵ and Kevin Winthrop⁶, ¹Stanford University Medical Center, Palo Alto, CA, ²Rheumatology, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly and Company, Kobe, Japan, ⁶Oregon Health & Science University, Portland, OR
Background/Purpose: Baricitinib (bari), an oral, selective inhibitor of Janus kinase (JAK) 1 and JAK 2, is approved in the EU for the treatment of moderately…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].